Clinical trial
Safety, Reactogenicity and Immunogenicity Study of the Drug "Sputnik Lite" for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Composition With Participation of Adult Volunteers.
NCT06057025 is registered in ClinicalTrials.gov with Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Reactogenicity and Immunogenicity Study of the Drug "Sputnik Lite" for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Composition With Participation of Adult Volunteers.
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 30, 2023
- Completion date
- December 31, 2024
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.